Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oxford BioTherapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7543
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxford BioTherapeutics Ltd (OBT) is a clinical stage oncology company that develops antibody drug conjugates for the treatment of variety of cancers. The company’s product pipelines currently includes T-cell based IO therapies including check point modulators; NK cell based IO therapies such as antibody dependent cell mediated toxicity (ADCCs); and Antibody drug conjugates (ADCs). Its therapeutic antibodies targets checkpoints restore anti-tumour immune function allowing the immune system to recognise and kill cancer cells. The company works in collaboration with companies for the development of component technologies to develop innovative ADCs. It operates through its offices in the UK and Switzerland. Oxford BioTherapeutics is headquartered in Abingdon, the UK.

Oxford BioTherapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Calculus Capital Invests USD2.6 Million in Oxford BioTherapeutics 11
Partnerships 12
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 12
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 13
Invenra Enters into Agreement with Oxford BioTherapeutics 14
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 15
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 16
Licensing Agreements 17
Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 17
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 18
Oxford BioTherapeutics Ltd – Key Competitors 19
Oxford BioTherapeutics Ltd – Key Employees 20
Oxford BioTherapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Corporate Communications 22
Jun 13, 2017: Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director 22
Feb 09, 2017: Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans 23
Product News 24
09/28/2017: Menarini Ricerche Attended the Brainstorming Meeting on CD38 and CD157 which was Held on September 21st-23rd 2017 at San Benedetto Po and Mantova (Italy) 24
03/01/2018: Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi M.D., Ph.D. 25
Clinical Trials 26
Sep 12, 2017: Oncology Research: New Opportunities for Menarini and OBT 26
Jun 21, 2017: Menarini Ricerche to Present the Most Recent Data About the Pre-Clinical Development of its Novel ABC Men1309/Obt076 at the 29th Pezcoller Symposium 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford BioTherapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Calculus Capital Invests USD2.6 Million in Oxford BioTherapeutics 11
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 12
Boehringer Ingelheim Exercises Option Agreement with Oxford BioTherapeutics 13
Invenra Enters into Agreement with Oxford BioTherapeutics 14
Oxford BioTherapeutics Enters Into Agreement With Boehringer Ingelheim To Discover Cancer Antibody Targets 15
Menarini Enters Into Agreement With Oxford BioTherapeutics To Develop Antibody-Based Anticancer Drugs 16
Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 17
Oxford BioTherapeutics Exercises Option for Licensing Agreement with Boehringer Ingelheim 18
Oxford BioTherapeutics Ltd, Key Competitors 19
Oxford BioTherapeutics Ltd, Key Employees 20
Oxford BioTherapeutics Ltd, Subsidiaries 21

List of Figures
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oxford BioTherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oxford BioTherapeutics Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sing Investments & Finance Limited (S35):企業の財務・戦略的SWOT分析
    Sing Investments & Finance Limited (S35) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Covanta Holding Corporation
    Covanta Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary Covanta Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bonavista Energy Corp (BNP):石油・ガス:M&Aディール及び事業提携情報
    Summary Bonavista Energy Corp (Bonavista) is an intermediate energy company, which acquires, explores for, develops and produces oil and natural gas from its assets in the provinces of Alberta, British Columbia and Saskatchewan. Its core operations are concentrated in the Glauconite and Falher plays …
  • Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析
    Summary Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of …
  • Triodos Bank NV:企業の戦略・SWOT・財務情報
    Triodos Bank NV - Strategy, SWOT and Corporate Finance Report Summary Triodos Bank NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Alliqua BioMedical Inc (ALQA):製薬・医療:M&Aディール及び事業提携情報
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc, is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s products comprise ultrasound healing therapy, human biologics, antimicrobial protecti …
  • William Hill plc (WMH):企業の財務・戦略的SWOT分析
    William Hill plc (WMH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • GoldStone Resources Ltd (GRL):企業の財務・戦略的SWOT分析
    Summary GoldStone Resources Ltd (GoldStone) is a mining and mineral exploration company. The company acquires, explores, develops and produces gold properties. It offers exploration projects such as Homase-Akrokeri permits, Manso Amenfi permits, Sangola permits, Oyem permits and Ngoutou permits, amo …
  • Redbiotec AG-製薬・医療分野:企業M&A・提携分析
    Summary Redbiotec AG (Redbiotec) is a biopharmaceutical company that develops prophylactic vaccines, which target various virus associated diseases. The company produces multi component virus like particles and other protein assemblies through its rePAX coexpression technology. It is developing prod …
  • Orly International, Inc.:企業の戦略・SWOT・財務分析
    Orly International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Orly International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Centogene AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Centogene AG (Centogene) is a biotechnology and genetic diagnostic company which offers genetic testing for rare hereditary disorders. The company provides diagnostic services including whole genome sequencing, whole exome sequencing, clinical exome sequencing, NGS panel genomic, carrier scr …
  • Trimble Solutions Oy:企業の戦略的SWOT分析
    Trimble Solutions Oy - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Vista Outdoor Inc:企業の戦略・SWOT・財務情報
    Vista Outdoor Inc - Strategy, SWOT and Corporate Finance Report Summary Vista Outdoor Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Idaho Power Co:発電所・企業SWOT分析
    Idaho Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • First Security Bank Inc:企業の戦略・SWOT・財務情報
    First Security Bank Inc - Strategy, SWOT and Corporate Finance Report Summary First Security Bank Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • OneMain Holdings Inc:企業の戦略・SWOT・財務分析
    OneMain Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary OneMain Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Boston Scientific Corp (BSX):企業の財務・戦略的SWOT分析
    Boston Scientific Corp (BSX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Valener Inc:企業の戦略的SWOT分析
    Valener Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Neuway Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Neuway Pharma GmbH (Neuway) is a provider of preclinical and clinical development for the treatment of central nervous system diseases. The company provides proprietary CNS drug delivery platform facilitates the transport of active drug substances through the blood-brain barrier. Its technol …
  • Astute Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Astute Medical Inc (Astute Medical), a subsidiary of BioMerieux SA is a diagnostic equipment provider. The company offers biomarker products such as nephro check test and astute meter. Its products are used in the field of identifying and validating biomarkers of acute kidney injury through …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆